Brainscape's Knowledge GenomeTM


Top Flashcards (Certified)
All Flashcards

RACP exam > Gastroenterology > Flashcards

Gastroenterology Flashcards

1
Q

What are autoimmune disorders associated with coeliacs disease

A

Autoimmune thyroiditis, type 1 DM, Addisons, Sjogrens, AI hepatitis, Primary biliary cirrhosis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Coeliacs is associated with what clinical signs

A

Splenic atrophy, IgA deficiency, Atrophic gastritis, Dermatitis herpetiformis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

What HLA is coeliacs disease associated with

A

HLA D23 or DQ8

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Antibodies to test in coeliacs disease

A

Anti TTG (can to IgA or IgG if IgA deficient) , Anti endomysial anti gliadin, if serology negative consider IgA deficiency producing false negative

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Small bowl biopsy findings for coeliacs

A

duodenal flattening / scalloping, lymphocytic lamina propria infiltration *CD4+ T cells, histological improvement needs 6 months, symptoms improve in 2 weeks

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

causes of villous atrophy

A

coeliacs, Autoimmune enteropathy, CVID, collagenous or tropical sprue, giardia, Crohns, GI lymphoma, eosinophilic gastroenteritis, TB, Whipples disease, Zollinger Ellison sx, other food intolerance

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Symptoms / signs of malabsorption

A

Anaemia (Fe, B12, folate deficiency), weakness ( K+), Bruising (vit K), Glossitis / angular stomatitis (vitamin B group deficiencies), Peripheral neuropathies (B1,B2), oedema (protein deficiency), Bone pain (osteomalacia),

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Faecal fat estimation in malnutrition

A

more than 7 g per day abnormal. Steatorrhea is one of the clinical features of fat malabsorption and noted in many conditions such as exocrine pancreatic insufficiency (EPI), celiac disease, and tropical sprue.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

B12 deficiency cause

A

Pernicious anemia is a relatively rare autoimmune disorder that causes diminishment in dietary vitamin B12 (cobalamin) absorption, resulting in B12 deficiency and subsequent megaloblastic anemia. It affects people of all ages worldwide, particularly those over 60.8. Antibodies to intrinsic factor in GI.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Causes of acute NON BLOODY diarrhoea

A

viral, bacterial (shigella, salmonella, campylobacter - mild), E coli, Cholera, clostridia, protozoan -> guardia, crytpsporidia, Cylospora, strongyloides, food toxins, Malaria

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Test for small bowel overgrowth

A

C14 glycocholate breath test - abnormal in bacteria overgrowth and ileal disease

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Slightly above average risk for colon ca screening regime

A

98% population, FOBT every 2 years life age > 50, consider sigmoidoscopy every 5 years from 50

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

causes of acute BLOODY diarrhoea

A

Shigellosis (bacillary dysentery), Enterohaemorrhagic E coli, Campylobacter, Yersinia, Salmonella, Amoebic dysentery, Antibiotic associated colitis, rarely schistosoma, tricuris

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Risk factors for risk stratification for colon ca

A

Age, symptoms, personal hx of bowel disease, family history of bowel cancer (1st degree v second degree) and age of onset, diet, lifestyle and smoking

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Cat 2 - moderately increased risk colon ca screening regime

A

1-2% population - Colonoscopy every 5 years from 50 OR every 5 years from 10 years younger than the earliest family member diagnosed. Consider FOBT in intervening years.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Cat 3 - colon cancer risk screening regime

A

<1% population.
FAP - flex sig yearly/ second yearly starting from age 12-15; then prophylactic surgery. I no po;yposis by age 35 then changed 3 yearly, then 5 yearly after age 50
HNPCC - colonoscopy every 1-2 years from age 25 or 5 years earlier than youngest family member

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Scope regime after polyps

A

adenomatous = villous or tubulovillous generally scope every 3 years if have hx of large >1cm non malignant polyps

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Treatment for stage II CRC

A

Surgical resection - Consider chemotherapy - 5FU, oxaliplatin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Treatment for stage III CRC

A

Adjuvant chemo (FOLFOX -FU + oxaliplatin, capecitabine)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Treatment for stage IV CRC

A

palliative surgery +/- palliative chemotherapy +/- adjuvant RT on case by case basis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Cetuximab / Panitumamab

A

EGFR - left sided CRC with RAS wildtype, SEs acne form rash but thought to be good sign of efficacy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Capecitabine (Xeloda) side effects

A

Diarrhoea, hand and foot syndrome (erythematous and desquamating feet and hands)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Oxaliplatin side effects

A

Peripheral neuropathy , liver toxicity, diarrhoea/ constipation, pulmonary fibrosis, rhabdomyolysis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Extracolonic manifestations of UC

A

Ankylosing spondylitis, arthritis, pCS/ cirrhosis, Ca bile duct, Amyloidosis, Anaemia, VTE, ulcers, Erythema nodosum, pyoderma gangrenosum, Uveitis, conjunctivitis, episcleritis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Antibody for Crohns and UC
ASCA (anti saccharomyces Cerevisiae - common yeast found in the bowel)
17
Disease severity of UC
Mild < 4 motions per day, normal HR/ temp, minimal bleeding (sulfasalazine /mesalazine - can use Azathioprine/6MP) Severe - > 6 motions per day, febrile, HR > 90, Abdo pain, bleeding ++ (cyclosporine salvage therapy, can use infliximab Fulminant - >10 motions per day, continuous bleeding, fever, tachycardia, Abdo pain and distension - IV/PO steroids, topical steroids (foam enema) 20% flare steroid resistant - surgery proctocolectomy + ileoanal reservoir
18
Causes of hepatosplenomegaly
Chronic liver disease with portal HTN, leukaemia, lymphoma, MPD, CMV, infiltration - sarcoid/ amyloid, Connective tissue disease (SLE), Acromegaly, thryotoxicosis
19
Ascites
Exudate > 25g/L protein
20
Causes of ascites
liver failure, portal HTN, abdominal malignancy, CCF, CRF/ASRF, infection - consider peritoneal TB
21
SAAG
Ascitic fluid albumin - serum albumin = if gradient > 11g/L the HAVE portal HTN, if gradient <11 then no portal HTN
22
Crohn's disease extracolonic manifestations
similar to UC except - more gallstones (PSC less common), renal disease (urate and oxalate stones) obstruction, infections from fistulae to the bladder, malabsorption, osteomalacia
23
Crohns disease treatment
Pred 15-40mg induction >60% effective at inducing remission, budesonide for mild ileo-caecal disease. AZA or 6MP slow onset 12 weeks strong evidence for remission induction and maintenance, use of over 2 steroid courses per year. Cease after 4 years if no attacks (20% relapse) MTX - IM if failed aza Infiximab / adamilumab (anti TNF) 75% require surgical intervention
24
5-ASA
Mesalazine (for L ileocolitis), Osalazine and basalazide (for L colitis), topical preparations available, antibacterial, anti inflammatory (via COX) and immunomodulatory effects
25
6-MP & AZA (MOA)
AZA rapidly absorbed metabolised to 6-MP -> purine analogues with no purine ribonucleotide synthesis and decreased cell proliferation -> immunomodulatory activity
26
Infliximab (MOA)
Monoclonal IgG.-IGg4 against TNFa, TNFa key inflammatory cytokine and mediator of intestinal inflammation -> increased expression in IBD, infliximab blocks TNFa in serum and at cell surface + lyses producing Macrophages and T cells via complement fixation and antibody dependent cytotoxicity
27
Hep B DNA / RNA ?
DNA
28
Outcomes of Hep B infection
75% transient and subclinical disease 30% Sx 1% fulminant hepatic failure 5% chronic HBV in adults note: 90% chronicity in neonates
29
HCC risk in HBV
risk 0.5% per year - high HBV DNA, male, older age, ETOH, smoking, high ALT, HBeAg positive, cirrhosis
30
Entecavir / Tenofovir
entecavir (nucleoside analogue), tenofovir (nucleotide analogue) advantages: ease of administration (once-daily oral dosing) well tolerated entecavir and tenofovir are highly potent and have a high genetic barrier to resistance disadvantages prolonged (potentially lifelong) therapy required risk of hepatitis flare when therapy is stopped adverse effects generally well tolerated tenofovir: minor reduction in bone mineral density; kidney impairment reported rarely, including Fanconi syndrome
31
peginterferon alfa-2a (an interferon)
Chronic Hep B advantages defined treatment duration (48 weeks) no risk of resistance also active against hepatitis D infection in patients with co-infection disadvantages weekly subcutaneous injection much more likely to cause significant adverse effects than oral antiviral drugs poor response rates can trigger an acute hepatitis flare not recommended in patients with cirrhosis or in pregnancy adverse effects influenza-like symptoms, anorexia, psychiatric disorders (eg depression, suicidal ideation), fatigue and weight loss are common can cause thyroid dysfunction and bone marrow suppression, and trigger autoimmune disease
32
Treatment of chronic Hep B
Treatment regimens For adults with chronic hepatitis B who require treatment, use: 1 entecavir 0.5 mg orally, daily OR 1 tenofovir disoproxil fumarate 300 mg orally, daily OR 1 tenofovir disoproxil maleate 300 mg orally, daily OR 1 tenofovir disoproxil phosphate 291 mg orally, daily. Peginterferon may be used instead of entecavir or tenofovir in selected adults with chronic hepatitis B who are not cirrhotic. Peginterferon is used more commonly in patients in the immune clearance (HBeAg positive chronic hepatitis) phase than those in the immune escape (HBeAg negative chronic hepatitis) phase. Peginterferon should only be used when recommended by a specialist with expertise in the management of viral hepatitis. The recommended dose is: peginterferon alfa-2a 180 micrograms subcutaneously, once weekly for 48 weeks [Note 5].
33
Child Pugh classifications
Ascites - absent / mod / tense Encephalopathy - None, grade I-II, grade III-IV Serum albumin - >35, 30-35, <30 Serum bilirubin - <34.2, 34 - 51, > 51 INR - < 1.7, 1.7 - 2.3, >2.3
34
HEP C natural progression
Exposure -> 75% Asx 25% Sx -> 80-95% persistance -> 5-20% clearance. IVDU, Blood Tx < 1992 Cirrhosis 20% is at 20 years Risk factors for progression to cirrhosis : ETOH, Steatosis, DMT2, Iron overload, mal > 40, HBV, immunosuppression, Genotype, viral load, response to Rx
35
35
Extrahepatic manifestations Hep C
2% - essential mixed cryglobulinaemia, Menbranoprliferatiuve GN, Porphyria cutanea tarda, Leukocytoclastic vascultitis.
36
Hep C treatment
Peg INFalpha and ribavirin Measure at 12 weeks >2 log decrease SEs - Peg INF a: malaise, fatigue, depression, neutropenia, thrombycytopaenia, thyroid disease, insomnia, diarrhoea, Ribavirin: Anaemia, rash , pruritic, highly teratogenic Contraindications: Severe depression, CCF, renal failure, pregnancy/inadequant contraceptions, ongoing drug use, Cirrhosis in HBV patients (risk severe flare)
37
HCC + HBV/ HCV and cirrhosis
HCC in HBV can develop in the absence of cirrhosis, HCC in HCV develops after cirrhosis
38
HCC diagnosis
histology 2% risk tract seeding OR 2cm arterial enhancing on 2 different modalities OR > 2cm arterial enhancing on single modality + AFP > 400
39
Treatment of HCC
Partial hepatectomy : Single lesion < 5cm, single lobe, no vascular invasion, no portal hypertension, good hepatic function (child Pugh A) 90% 5yr survival good pt selection Liver transplantation - unresectable due to poor liver reserve AND solitary lesion < 5cm Or multiple tumours < 3cm largest < 4,.5cm and total < 8.5 cm AND no vase invasion, regional nodes / mets, 75% 5 yr surv. ETOH Ablation, RF ablation, trans arterial chemoembolisation (doesnt inc survival), stereotactic radiotherapy for mets, sorafenib increases survival.
40
Portal hypertension def and mortality
> 12mmHg (normal < 6), >20 mmHg is a predictor of complications, ~50% cirrhotics develop varies. Child Pugh determines mortality; A 1%, B 25-30%, C 50% mortality.
41
portal hypertension treatment
Antibiotics (timentin) 72 hours, octreotide (dec rebleed risk, no inmrpoved mortality) terlipressin / banding - improves mortality. TIPPS if all else fails, Hypertensive gastropathy -> argon plasma coagulation
42
Portal hypertension prophylaxis
Propranolol - dec bleed risk by 50%, no clear mortality benefit Risk of bleeding- vary size large 30%and annual risk ,c child Pugh class - best predictor of mortality, red spot - best predictor of bleeds, Hepatic venous pressure of > 18 best predictor of complications, continued ETOH abuse
43
Hep B disease progress
44
Autoimmune pancreatitis
swollen sausage shaped pancreas + low attenuation at head Ddx Is pancreatic cancer - associations with UC, Sjogrens and RA - Test ANA, Anti smooth muscle Abx, increased IgG4
45
Hereditary pancreatitis
AD inheritance, needs yearly US and highs risk of chronic pancreatitis and pancreatic cancer, ANA and IgG4 +ve
46
Autoimmune hepatitis
HLA DR3 & 4, jaundice anorexia fatigue, ALT / AST elevated, hypergammaglobulinaemia, Extrahep manifestation in 10-50% autoimmune thyroid disease, synovitis /arthoropathy, ITP, DMT1, haemolytic anaemia, vitiligo, alopecia, CREST, RA< Celiac, UC, PSC Treatment: Prednisolone +/- azathioprine Type 1"classic": ANA, anti smooth muscle, anti actin, anti soluble liver / pancreas antigen Type 2 - Anti LMK-1, anti liver cytosol 1
47
Primary biliary cirrhosis onset and symptoms
onset > 30 T lymphocyte mediated attack on bile ducts, 50% asymptomatic Symptoms: Prurutis, fatigue, hyperpigmentation, PBC arthropathyDiagnosis: inc ALP, inc GGT, AST/ALT normal, antimitochondrial ABs - AMA in 05%, ANA esp ant centromere - in creased risk of progression to liver failure, hyperlipidaemia.
48
PBC diagnosis
Diagnosis: inc ALP, inc GGT, AST/ALT normal, antimitochondrial ABs - AMA in 95%, ANA esp ant centromere - in creased risk of progression to liver failure, hyperlipidaemia.
49
PBC treatment
Ursodeoxycholic acid (improves survival, dec progressions in early stage disease, improves biochem, dec varies, dece liver transplantation)
50
PBC associations
Sjogrens / Sick Sx, Scleroderma / CREST, RA, thyroid dysfunction, IBD
51
PSC features
70% associated with IBD, Chronic cholestatic liver disease characterised by liver inflammation and fibrosis in intra and extra hepatic bile ducts. Smoking. Prognosis 85% 5 year survival; Cholangiocarcinoma in 10-20%the, HCC in 2%
52
PSC diagnosis
ANCA in 65-95% ANA esp anti centromere - increased risk of progression to liver failure Hyperlipideamia
53
PSC treatment
nothing proven to alter progression of disease Ursodeoxycholic acid improves LFTs but does not have survival benefit or delay need for liver transplant PSC recurrence 8-20% decreased varicose, decreased liver transplantation
54
Define acute liver failure
55
What are the clinical features of acute liver failure
56
Kings college criteria for paracetamol overdose
57
Kings college criteria for non paracetamol overdose
58
Child Pugh scoring
59
What would you expect to show on the results of an acetic tap in the event of cardiac ascites?
High SAAG >11 High ascetic protein >2.5
60
Explain management of spontaneous bacterial peritonitis
Ceftriaxone 2g/ cefotaxime (cipro for penicillin allergy)
61
Contraindications to terlipressin
IHD, cardiac arrhythmias, cardiomyopathies, obliterative arterial disease of the lower limbs, asthma, COPD, CVD, age >70

RACP exam (4 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2025 Bold Learning Solutions. Terms and Conditions